Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 15 Sep - Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (LODR) Regulations 2015.
Source: Bse
Jupiter Life Line Hospitals Limited (JLHL)
Micro CapPharma stocks · Micro cap · NSE
Jupiter Life Line Hospitals Limited (JLHL) operates a chain of multi-specialty quaternary care hospitals in Western India, with facilities in MMR, Pune, and Indore. The company recently operationalized its Dombivli hospital and acquired land for a new 400-bed hospital in BKC, aiming to expand its bed capacity to 2,900.
Data qualityFresh enough for analysisQuote updated 21 Oct, 04:45 am ISTDetails
Quote21 Oct, 04:45 am IST
Base fundamentals14 Oct 2026 · screener
Latest result31 Jul, 10:27 pm IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
60BullishSMA20 -11.6% / mo · MACD + · near 52W low · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 34
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
JLHLD candles · FIT view-2.2%Latest close ₹243.90 on 2026-10-19
Bar
-1.3%
RSI
33
MACD hist
0.09
52W pos
9%
2026-10-19O ₹247.00H ₹249.90L ₹242.20C ₹243.90Vol 65,751 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
JLHLNifty PharmaNifty 500
- JLHL
- -21.7%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- -16.2 pp
Chart stats
19 Oct 2026- From 52W high
- -28.3%
- 52W range position
- 9%
- ATR (14)
- 4.1%
- Volume vs 20D
- 0.27x
- Avg traded value
- ₹6 Cr
- 20D price channel
- ₹235 - ₹280.3
₹340
₹235 - ₹340
₹10.1
Latest completed session
20-session average
31.9% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is consistent.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · WATCHLIST43
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad2
Revenue +16.4% · PAT -13.6% YoY
Technical
Bullish60
Price trend and sector-relative-strength timing.
Valuation
Legacy model+5.2%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence70
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Bad · 2/100PAT -14% YoY · margin compression · Rev +16% YoY · +6% QoQ
Filed 31 Jul 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹411 Cr | +16.4% | +5.9% |
| EBITDA | ₹79 Cr | +1.3% | -11.2% |
| Operating margin | 19.0% | -300 bps | -400 bps |
| PAT | ₹38 Cr | -13.6% | -24.0% |
| PAT margin | 9.3% | -321 bps | -364 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 41.70
- P/B
- 5.14
- EV/EBITDA
- 19.56
- Market Cap
- 7963.00Cr
Profitability
- ROE
- 13.10%
- ROCE
- 14.80%
- ROA
- 7.96%
- Dividend Y
- 0.08%
Growth (CAGR)
- Revenue 5Y
- 25.00%
- EPS 5Y
- 143.00%
- Revenue 3Y
- 19.00%
- EPS 3Y
- 37.00%
Balance Sheet
- Debt/Equity
- 0.38
- Interest Coverage
- 9.30×
- Altman Z
- 8.09
- Book Value
- 47.10
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 3/5
- OCF
- 268.00 Cr
- EPS TTM
- 5.72
Shareholding
- Promoter Hold
- 40.91%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 11%
Financial History
Updated 20/10/2026
Revenue
₹ CrLatest: 1,500+15.2% vs prev
Net Profit
₹ CrLatest: 194+0.0% vs prev
Return on Equity
%Latest: 12.6-12.2% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term trend down. RSI 33.
- Price below SMA200 (long-term downtrend) — short-term bounces likely countertrend.
- SMA20 falling (~13.1% over last month) — short-term momentum negative.
- RSI(14) at 33 — sideways, no extreme reading.
- MACD above signal but histogram contracting — bullish momentum cooling.
- Within 5% of 52-week low — testing support.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
37
RS percentile
Stage 1 Base / Transition
1M return
-12.9%
3M return
-21.7%
6M return
-5.6%
1Y return
-21.1%
RS 1D
-1
RS 20D
-15
Sector rank
#1
Industry rank
#17
Stage evidence
- Price is 11.4% below the 30-week proxy without full trend alignment.
- The 30-week proxy changed +0.1% over 20 sessions.
- The moving-average structure does not confirm Stage 2 or Stage 4.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 83.2-0.25%
RS vs Nifty 50083
Valuation & peers
U-Score 43 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
Valuation & peers
U-Score 43 · legacy U-Score band WATCHLIST · valuation evidence and comparable companies
WATCHLIST
Fundamental score breakdown
U band · WATCHLISTValuation2/30
Growth21/25
Quality3/20
Balance Sheet8/15
Cash Flow3/10
Piotroski
8/9 (+5)
Penalties
1
Raw sum
43
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
43/100 · legacy band WATCHLIST
Positive drivers
- Piotroski is strong at 8/9.
- Growth contributes 21/25 to the score.
- Balance sheet contributes 8/15 to the score.
Main drags
- Valuation is weaker at 2/30; verify the latest quarterly trend.
- Quality is weaker at 3/20; verify the latest quarterly trend.
- Cash flow is weaker at 3/10; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
41.7
PB
5.1
EV/EBITDA
19.6
ROE
13.1%
ROCE
14.8%
FCF Yield
—
Debt/Equity
0.4
MoS
+5.2%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
43
Previous: 43
Legacy U-Score band
WATCHLIST
Previous: WATCHLIST
Margin of safety
+5.2%
Previous: +5.2%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
42
42
42
42
43
43
43
43
43
43
43
43
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹77.86
-213.3% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹257.4
+5.2% MoS
PEG
0.41
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
HCG
Micro
Healthcare Global Enterprises Limited
Healthcare Services
match 166
28
182.0
2.5%
-727%
OVERVALUED
PARKHOSPS
Micro
Park Medi World Limited
Healthcare Services
match 165
44
37.2
16.8%
+22%
WATCHLIST
AGARWALEYE
Micro
Dr. Agarwal's Health Care Limited
Healthcare Services
match 159
30
99.3
6.0%
-122%
OVERVALUED
ARTEMISMED
Small
Artemis Medicare Services Limited
Healthcare Services
match 158
39
44.2
12.0%
+10%
WATCHLIST
DRAGARWQ
Small
Dr Agarwals Eye Hospital Limited
Healthcare Services
match 154
61
32.7
24.2%
+28%
UNDERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Where growth can come from, and what can break the case
Thesis under stressReviewed 2026-06-10T07:07:44.466Z
Management commentary snapshot
JLHL reports 15.2% YoY total income growth in FY26, but PAT growth was minimal at 0.2% YoY due to initial losses from the new Dombivli hospital, higher depreciation, increased finance costs, and new labor code changes.
While top-line growth remains robust, profitability is under stress due to significant investments in new capacity. The operationalization of Dombivli hospital ahead of schedule impacted Q4 and FY26 financials with initial losses and higher depreciation. The company's aggressive expansion strategy requires close monitoring of ramp-up timelines and debt levels.
Current business mix
Payor Mix (FY26)
Latest issuer-disclosed distribution across 3 reported categories.
Self Payors55.4%
Insurance Companies43.6%
Government Schemes1.0%
Growth engines
Bed Capacity Expansion
Company is scaling bed capacity to 2,900, with 1,700 beds added post-IPO at an average cost/bed of ~Rs 1.5 Cr (including land cost).
Strategic Land Bank
Acquisition of land at BKC for a 400-bed hospital and existing land bank in high-demand micro markets support future growth.
Phased Commissioning
Strategy of phased commissioning for new projects like Dombivli and Pune II aims to optimize capital deployment.
Operating Leverage
Management expects strong operating leverage from consolidated scale as new hospitals ramp up.
Capacity and execution
Dombivli Hospital
Operationalized on Feb 25, 2026, ahead of Q1 FY27 schedule. Phase I has 300 beds fit-out, 200 beds operational, with civil construction for 500 beds completed. Capex ~Rs 425 Cr.
BKC Hospital
Land acquired for a 400-bed multispecialty quaternary care hospital. Land cost Rs 354 Cr for an 80-year lease. Project in documentation & registration phase.
Pune II Hospital
A 500-bed greenfield project is currently under construction.
Mira - Bhayandar Hospital
A 300-bed project is at the conceptualization and planning stage.
Tailwinds
Ahead-of-Schedule Project Delivery
Dombivli hospital was operationalized before its scheduled launch date of Q1 FY27, demonstrating execution capability.
Strong Location for New Projects
BKC hospital site is strategically located, with over 2/3 of Mumbai's population within a 45-minute drive, adjacent to Bullet Train station.
Headwinds
Initial Ramp-up Losses
Q4 financials were impacted by Rs 9.4 Cr opex losses from Dombivli hospital during its initial ramp-up phase.
Higher Depreciation
Depreciation expense increased following the commercialization of the Dombivli hospital, impacting profitability.
Increased Finance Costs
Finance costs increased YoY due to higher gross debt levels undertaken to fund ongoing capital expenditure.
New Labour Code Impact
PAT was impacted due to statutory changes from new labour codes.
Risk radar
Execution Risk for New Projects
Large-scale expansion projects (Pune II, Mira-Bhayandar, BKC) carry risks of time and cost overruns.
Ramp-up of New Hospitals
New hospitals like Dombivli will incur initial operational losses and higher depreciation, impacting near-term profitability until full utilization.
Increased Debt Levels
Gross debt has increased to fund ongoing capex, leading to higher finance costs and potential balance sheet strain.
Management accountability
What management said, and what results must prove
Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.
Analyst reading lens
Compare BOTH
YoY comparison is essential for assessing full-year performance and growth trends. QoQ comparison is relevant for Q4FY26 to understand the immediate impact of the Dombivli hospital's operationalization on sequential profitability and costs.
Sector KPIs management disclosed
Total Income
Total Income grew 15.2% YoY to Rs 1,499.8 Cr in FY26 (vs Rs 1,302.4 Cr in FY25). Q4FY26 Total Income grew 15.1% YoY to Rs 387.8 Cr.
EBITDA
EBITDA grew 14.4% YoY to Rs 343.3 Cr in FY26 (vs Rs 300.1 Cr in FY25). Q4FY26 EBITDA grew 12.3% YoY to Rs 89.2 Cr.
EBITDA Margin
EBITDA Margin was 22.9% in FY26 (vs 23.0% in FY25). Q4FY26 EBITDA Margin was 23.0% (vs 23.6% in Q4FY25).
PAT
PAT grew 0.2% YoY to Rs 194.2 Cr in FY26 (vs Rs 193.8 Cr in FY25). Q4FY26 PAT grew 11.5% YoY to Rs 50.2 Cr.
Management forward view
Landmark Year for Expansion
Management states FY26 was a landmark year with BKC land acquisition and Dombivli hospital operationalization.
Western India Leadership
Operationalizing Dombivli cements leadership in Western India with four hospitals in MMR, two in Pune, and one in Indore.
Existing Hospital Performance
Thane, Pune, and Indore hospitals are performing on expected lines, and Pune South construction is progressing on schedule.
Thesis monitor
Numbers and claims to verify in the next filings
| Checkpoint | Current evidence | What to verify next |
|---|---|---|
| Dombivli Hospital Ramp-up | 200 beds operational, 300 beds fit-out completed. | Progress in operationalizing remaining fit-out beds and achieving higher occupancy rates to mitigate initial losses. |
| Pune South Construction | Progressing on schedule. | Timely completion and commissioning of the 500-bed Pune II project without significant cost overruns. |
| BKC Hospital Development | Land acquired, documentation & registration phase. | Progress in planning, regulatory approvals, and commencement of construction for the 400-bed facility. |
| Debt Levels and Finance Costs | Gross debt increased to Rs 500.9 Cr (non-current) and Rs 7.6 Cr (current) in Mar-26. | Management of debt and finance costs as capex continues, and impact on overall profitability. |
Verification checkpoints are IndiaPulse research interpretation, not investment advice.
Trust Score
70Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 63rd percentile of the scored universe and 50th percentile within Pharma. Main check: cash conversion is weak at 55/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
52 docs text-extracted · 21 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
63rd percentile
overall median 67 · Pharma: 50th pctile, median 70 · Micro: 43rd pctile, median 73
Evidence depth
Financial-only
52 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
78
strong · holding, pledge, alignment
Cash flow
55
watch · profit to cash conversion
Balance sheet
89
strong · leverage and solvency
Discipline
58
watch · capital discipline
Results
75
strong · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸4/4 latest quarters had positive YoY revenue growth.
- ▸OPM spread across recent quarters is 5%.
Trust risks
- ▸ROCE trend is -3.5%.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Jupiter Life Line Hospitals Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Investor presentationAug 2026
Aug 2026 · PPT
Source: Bse
Concall transcriptAug 2026
Aug 2026 · Transcript
Source: Bse
Annual reportJul 2026
Jul 2026 · Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 ("Listing Regulations") 29 Jun - 24th AGM on July 17, 2026; annual report FY2025-26 dispatched to unregistered email members.
Source: Bse
AnnouncementJul 2026
Jul 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 25 Jun - Intimation of Newspaper Advertisement for the 24th Annual General Meeting of the Company to be held on Friday, July 17, 2026, through Video Conference (VC') …
Source: Bse
Annual reportJul 2026
Jul 2026 · Reg. 34 (1) Annual Report. 24 Jun - Annual Report 2025-26 filed; AGM on July 17, 2026 via VC/OAVM.
Source: Bse
AnnouncementJul 2026
Jul 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 2d - Intimation of Newspaper Publication of the 24th Annual General Meeting of the Company to be held on Friday, July 17, 2026 through Video Conference ('VC') …
Source: Bse
Annual reportJul 2026
Jul 2026 · Reg. 34 (1) Annual Report. 24 Jun - Annual Report 2025-26 issued; AGM scheduled for 17 July 2026 via VC/OAVM.
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 3 Aug - Intimation of Newspaper Publication for Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30,2026.
Source: Bse
AnnouncementJun 2026
Jun 2026 · Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 3 Jun - Jupiter Life Line Hospitals to attend Macquarie group meeting in Mumbai on 8 June 2026.
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 3 Jun - Intimation of Schedule of Analyst / Institutional Investor meetings under the SEBI (LODR) Regulations 2015.
Source: Bse
Concall transcriptMay 2026
May 2026 · Transcript
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.